Aclairo’s previous experience as FDA supervisors, reviewers, and drug developers has forged a unique comprehension of the product-specific complexities of pharmaceutical drug development. The Aclairo advantage is our experience-based synergistic approach to providing strategic, scientific review and regulatory services. This has proven to be our greatest asset in focusing and streamlining our clients’ drug development efforts, reducing both time and costs, leading to success.

Aclairo is a wholly owned subsidiary of Experimental Pathology Laboratories, Inc. EPL provides a comprehensive range of toxcicologic pathology-oriented services that are designed to provide the best scientific expertise available in the most cost effective manner (www.epl-inc.com)

Aclairo Pharmaceutical Development Group, Inc.

Org chart

Teams

Offices